Introduction &
Improved recognition, diagnosis and treatment of risk factors for micro-and macrovascular diseases and complications such as diabetes mellitus, hypertension and dyslipidaemia, should be among the top priorities of any healthcare system. Looking at the German situation in particular, we need more insight into the prevalence and nature of these risk factors in routine medical care. Transparency remains poor overall. Patients T2D history, especially older subjects had more favourable values. With regard to age, a higher percentage of patients had an HbA 1c ≥ 7.0 % (42.0 % and 40.6 % ) in the 45 -54 and 55 -64 year olds. With respect to the correlation between HbA 1c and treatment modality, we identifi ed the best metabolic control in T2D patients without drug therapy for diabetes, and the worst in patients on combination regimens (OAD / insulin). The average duration of diabetes in the various treatment groups differs substantially. The average duration was highest (12.1 y) in the insulin group. Oral treatment was the predominant treatment modality in all HbA 1c categories. Conclusion: T1D treatment needs to be improved overall. The situation as regards T2D is less clear-cut. When people with T2D start requiring more intensive and complex treatment in response to disease progression, the treatment efforts of patients and physicians evidently fail to keep up with the actual pace of metabolic deterioration. Early and strict alignment with approximately normal HbA 1c targets is essential. Close attention should be paid to T2 diabetics with a 5 -9-year diabetes history, with the aim of preventing any loss of metabolic control. Likewise, patients aged 45 -64 y and younger men require more attention. mary care has the following objectives: to determine (1) the prevalence of cardiovascular risk factors, (2) frequency in subgroups and (3) combination of risk factors in primary care patients, and (4) the degree of met and unmet medical needs in this population ( Wittchen et It is well documented, both for patients with type 2 diabetes (T2D, DM type 2) and for subjects with type 1 diabetes (T1D, DM type 1), that the onset of micro-and macrovascular comorbidities and complications depends to a crucial extent on the quality of diabetes control (among other factors) ( The aim of DETECT is to acquire nationwide representative data for primary care in Germany. The main study was designed in the format of a nationwide prospective survey with a cutoff date [2003] , and provides valuable and profound insights into the state of health and care of patients in primary care on the survey date. This paper reports the results of the point prevalence survey. The objectives are: § To provide information on the current quality of glycaemic control of people with diabetes in primary care (due to their clear numerical superiority, the main focus is on type 2 diabetic patients); § To explore associations between quality of control and key parameters such as gender, age, duration of diabetes, and treatment modality; and fi nally § To identify patient subpopulations -in terms of gender, age and duration of diabetes -with inadequate metabolic control in real-life clinical settings, who are likely to have a correspondingly higher risk of developing micro-and macrovascular comorbidities and complications. ( Royall, 1986 ) . The association of HbA 1c with age and duration of disease was estimated by nonparametric kernel regression ( Gasser and M ü ller, 1979 ) using the epanechnikov kernel and a bandwidth of 10. The association of HbA 1c and dichotomous treatment modalities were visualized by applying generalized additive models ( Hastie and Tibshirani, 1987 ) .
Material and Methods

Results
&
Survey population
15.2 % of the adults (over 18 years) reported in the cross-sectional part of DETECT were identifi ed as people with diabetes. Out of the total study population of 55,518 adults, 8465 people were classifi ed by their primary care physician as having diabetes. The diabetic population was divided into 277 with DM type 1 (50.5 % female, having a lower mean age [43.2 years] and a longer average duration of diabetes [20. 8 years], representing 0.5 % of the total study population); and in 8188 with DM type 2 (51.3 % female, having a higher mean age [66.3 years] and an average diabetes duration of 7.8 years, representing 14.7 % of the total study population). As was to be expected, patients with T1D were only treated with insulin. The majority of patients with T2D were treated according to a stepwise treatment plan as proposed in the 2002 German national treatment guidelines for DM type 2 (NVL T2D: N ationale V ersorgungs l eitlinie T2D) and other guidelines. The mean age and average duration of diabetes in the various treatment groups (no treatment, diet & exercise, oral treatment, tablets & insulin, insulin) fi t very well to a stepwise treatment algorithm. For 762 patients with T2D, the type of glucose lowering treatment was not given. For 507, it was " no treatment " ; for 1017, " diet & exercise " . " OAD " (oral anti diabetic drug(s)) was stated for 3700, " OAD & insulin " for 942, and " insulin " for 1260 patients. For the purpose of this paper, patients with " no treatment " and patients with " diet & exercise " are combined in a single " no glucose lowering drug " group; see Table 1 and ᭹ ᭤ Fig. 4 . Table 1 presents more details on the basic characteristics of the survey population. It is important to remember that, in patients with T2D, treatment modalities are not mere descriptions of the therapy administered to patients; the type of treatment also correlates to some extent with the severity of the diabetes. Whereas in the T1D population, the men were somewhat older than the women (mean age of 44.5 y vs. 41.9 y, p = 0.133) and had a somewhat longer diabetes history (mean diabetes history 21.6 y vs. 20.1 y, p = 0.342), the opposite applies in the T2D population (mean age of 65.3 y for men vs. 67.3 y for women, p = 0.000; mean diabetes history 7.6 y vs 8.1 y, p = 0.000). This gender-specifi c phenomenon applies to a varying degree for all treatment modalities in T2D ( Table 1 ) .
HbA 1c -age and duration of diabetes
An HbA 1c reading is reported for 220 adults with a diagnosis of DM type 1 (see Table 2 . In Tables 2, 3 the overall reading is indicated in italics and values above the overall reading are shown in bold). The mean HbA 1c was 7.4 ± 1.4 % ; 7.5 ± 1.4 % (n = 113) in men and 7.4 ± 1.3 % (n = 107) in women. The percentage of persons with a HbA 1c of ≥ 7.0 % was 58.2 % , with a higher prevalence in men (60.2 % ) and a slightly lower prevalence in the female TD1 population: 56.1 % . Men in the 18 -34 age group had a high average HbA 1c of 7.9 % , and a high proportion of insuffi ciently controlled HbA 1c : 70.0 % . Women in the 65 -74 age group likewise: 8.0 % and 75.0 % , respectively. The lowest mean haemoglobin A 1c (7.1 % ) was found in men in the 35 -44 age group. The corresponding fi gure in the female 18 -34 and 35 -45 age groups was 7.2 % . The lowest percentage of individuals with poor control (45.5 % ) was seen in the 65 -74 age groups in men and in the 35 -55 age group in women (45.8 % ). With respect to the reported " duration of diabetes " , men with a diabetes history of 5 -9 y had the highest average haemoglobin A 1c (8.1 % ). In the female population, the highest average HbA 1c (7.7 % ) was in subjects with a disease history of 25 y and longer. In the male population, the prevalence of HbA 1c ≥ 7.0 % was lowest (50.0 % ) in the 15 -19 y category. In the female population, the category with the lowest prevalence (38.5 % ) was 0 -4 y. A more complex map of HbA 1c readings was found in adults with a diagnosis of DM type 2. Data are available from 8188 people, which allows more specifi c analyses for T2D. Table 3 and ᭹ ᭤ Fig. 1 show the proportions of patients with a HbA 1c of ≥ 7.0 % in the DETECT population of people with T2D and in subpopulations classifi ed by gender, age and duration of diabetes. ᭹ ᭤ Figs. 2, 3 show the associations between (mean) haemoglobin A 1c and the reported age / duration of diabetes. The overall mean HbA 1c was 6.89 % ± 1.2 % (n = 6891). Men (n = 3359) and women (n = 3532) did not differ. The overall percentage of individuals with an HbA 1c ≥ 7.0 % was 38.8 % . The prevalence in men was slightly better than in women (37.8 % vs. 39.8 % ). Table 3 and ᭹ ᭤ Fig. 1 show a clear picture: All subgroups of individuals affected by T2D, in all age groups, with a diabetes history of 10 years and longer had proportions of patients with insufficiently controlled diabetes above the overall percentage, in most cases above 50 % . In these subgroups, roughly every second patient was insuffi ciently controlled (based on a threshold haemoglobin A 1c of 7.0 % ). In these patients with a diabetes history ≥ 10 y, the average HbA 1c was 7.15 % ; this is above the overall mean as well. In " younger " women with a longer history of diabetes -see Table 3 -we fi nd prevalences of individuals with HbA 1c ≥ 7.0 % of up to 100 % . In these subgroups of " younger " women with a longer diabetes history, the average HbA 1c in most cases exceeded 8.0 % . Table 3 shows that, in addition to subpopulations with a disease history of ≥ 10 y, insuffi ciently controlled T2D (HbA 1c ≥ 7.0 % ) was relatively often found in men aged 18 -34 y with a diabetes duration of up to 4 y (only a limited number of persons), men aged 35 -64 y, and women aged 45 -74 y, in each case with a diabetes history of 5 -9 y. Again, the average HbA 1c followed the trend and was higher as well, ranging in these subpopulations from 7.0 % to 7.6 % (the latter in men aged 18 -34 with a diabetes history of 0 -4 y). With respect to the age groups of T2 diabetics in DETECT, the 45 -54 and 54 -64 year olds stand out in terms of glycaemic metabolic control. We found the highest prevalences of haemoglobin A 1c ≥ 7.0 % (42.0 % and 40.6 % , prevalence odds ratio vs. all other age classes 1.2, 95 % confi dence interval: 1.04 -1.3) and highest mean HbA 1c readings (7.1 % and 7.0 % ) in these age groups (Mean HbA 1c : 6.9 % for age groups 18 -34 y, 35 -44 y and 65 -74 y; 6.8 % for age group ≥ 75 y). In T2D the HbA 1c rises in response to the duration of diabetes in the DETECT population. The mean value was 6.7 % in T2 diabetics with a disease history of 0 -4 y, 6.9 % for a disease history of 5 -9y, 7.1 % for 10 -14 y, 7.1 % for 15 -19 y, 7.3 % for 20 -24 y, and 7.2 % for ≥ 25 y. ᭹ ᭤ Fig. 2 shows the trend for all T2 diabetic patients and for the two genders separately. The T2D population showed a moderate and steady rise during the fi rst decade of disease in the average haemoglobin A 1c estimated from the sample for the total population. With a duration of diabetes of approximately 10 years, the curves for men and women become disparate, with the latter curve displaying a steeper gradient. The rise is somewhat more marked between year 10 and year 15, approximately, but subsequently fl attens, especially for the men studied in DETECT. Univariate analysis per year disclosed a progression of HbA 1c of an average of 0.08 % points in arithmetic terms. The progression was somewhat greater in women (0.09 % points) and less in men (0.07 % points) (p of 0.000 in either case). In arithmetic terms, there is a slight average decline per year of age, the mean being 0.004 % points (p = 0.004). In men, the decline is 0.006 % points (p = 0.009); in women, it is 0.003 % points (p = 0.127). The curve in ᭹ ᭤ Fig. 3 shows a metabolic control level with much higher mean HbA 1c values for younger men than for younger women. The inverse situation applies from an Table 1 
HbA 1c -treatment
Differences in the quality of diabetes control between the treatment groups were identifi ed in the T2 diabetes population. Table 1 already contains important information on the mean HbA 1c . In the DETECT population, the mean HbA 1c was 6.2 ± 0.8 % (both genders) in patients in the " no glucose lowering drug " treatment category (mean duration of diabetes 5 years), 6.9 ± 0.9 % (both genders) under treatment with OAD (mean diabetes history: 7 years), 7.5 ± 1.3 % (men: 7.5 % and women 7.6 % ) under combination treatment (OAD & insulin, mean history of diabetes: 11.5 years), and, fi nally, 7.3 % (men 7.2 % and women 7.4 % ) in subjects on insulin therapy (mean duration of diabetes 12.1 years). The corresponding prevalences in T2 diabetics with an HbA 1c ≥ 7.0 % were as follows (see Table 1 . Diabetics see their doctor more frequently than non-diabetics. Hence, the percentage of patients with a documented diagnosis of diabetes in the nationwide DETECT point prevalence study is in the expected range, based on the regional fi gures available. At fi rst glance, the frequency of a diagnosis of T1D (see Table 1 ) in the DETECT sample appears to be rather low, in relation to the 0.5 % prevalence in the overall population cited among others by H ä ussler et al. (2006) . In a point prevalence population such as for DETECT, one would expect a higher level than 0.5 % . However, it is important to remember that T1 diabetic patients in Germany more commonly receive treatment at special diabetology practices. According to Aldenhoven et al. (2002) values both for men and for women. The results of the DETECT point prevalence survey can be considered as being representative of primary care in Germany.
The results on quality of glycaemic metabolic control for the overall DETECT population (T1D: 7.4 % , T2D: 6. In T2D patients with higher HbA 1c levels and a longer diabetes history, OAD / insulin combinations and insulin-alone regimens are more common, as is to be expected. The HbA 1c levels remain fairly high on both treatment modalities in the primary setting, however. The causes are likely to be manifold. The potentials shown for these two treatment modalities in the experimental settings of clinical trials do not seem to unfold fully in real-life settings, in the manner in which they are currently put into practice and, above all, when they are put into practice. Interestingly, the mean age of patients receiving the various treatment modalities does not differ signifi cantly.
Conclusion &
T1D treatment in primary care is inadequate overall. Further improvement measures are required here. The situation is less clear-cut with respect to DM type 2. Glycaemic control is not poor overall, especially in patients with a shorter diabetes history. However, the inevitable impression is that the efforts of patients and physicians to achieve metabolic control tend to lag behind the actual metabolic deterioration in the bulk of the T2D population, especially when treatment needs to become more intensive and complex as a result of disease progression. Increased attention should be paid to people with DM type 2 with a 5 -9 history of disease, before any loss of metabolic control. In addition, patients in the 45 -54 and 55 -64 age groups, and younger men require attention, i.e., people with T2D who are commonly still part of the working population.
